Lexicon Pharmaceuticals, Inc. (LXRX)
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreKey Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Dr. Michael S. Exton Ph.D.
|
CEO & Director | 1.15M | -- | 1970 |
|
Mr. Scott M. Coiante
|
Senior VP & CFO | 646.29k | -- | 1967 |
|
Mr. Brian T. Crum
|
Senior VP, General Counsel & Secretary | 687.37k | -- | 1973 |
|
Ms. Wendy E. McDermott
|
Senior Vice President of Human Resources | 580.45k | -- | 1971 |
|
Dr. Craig B. Granowitz M.D., Ph.D.
|
Senior VP & Chief Medical Officer | 789.53k | -- | 1965 |
|
Ms. Kristen L. Alexander
|
Vice President of Finance & Accounting | 379.81k | -- | 1968 |
|
Ms. Lisa M. DeFrancesco
|
Senior Vice President of Investor Relations & Corporate Communications | -- | -- | 1980 |
|
Dr. Suma Gopinathan M.S., Ph.D.
|
Senior Vice President of Discovery | -- | -- | 1973 |
|
Ms. Rachel Yap Martens
|
Senior VP & Chief Commercial Officer | -- | -- | 1984 |
Lexicon Pharmaceuticals, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 81
Description
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes. It also commercializes INPEFA (sotagliflozin), a once-daily oral tablet to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, CKD, and other cardiovascular risk factors. In addition, the company develops LX9851, an orally-delivered small molecule drug candidate for the treatment of obesity and associated cardiometabolic disorders, and pilavapadin (LX9211), an orally-delivered small molecule drug candidate for the treatment of neuropathic pain. It has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Corporate Governance
Upcoming Events
November 5, 2026 at 1:30 PM UTC
Lexicon Pharmaceuticals, Inc. Earnings Date
